BrightGene Bio-Medical Technology
BrightGene Bio-Medical Technology Co., Ltd., commonly referred to as BrightGene, is a leading biopharmaceutical company headquartered in China. Established in 2003, the company has made significant strides in the development of innovative therapies, particularly in the fields of oncology and infectious diseases. With a strong focus on research and development, BrightGene offers a range of unique products, including advanced drug formulations and cutting-edge biopharmaceuticals. Their commitment to quality and innovation has positioned them as a key player in the global biomedicine market. Notable achievements include successful collaborations with international partners and a robust pipeline of drug candidates, underscoring BrightGene's dedication to improving patient outcomes worldwide.
DitchCarbon Score
How does BrightGene Bio-Medical Technology's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
BrightGene Bio-Medical Technology's score of 0 is lower than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
BrightGene Bio-Medical Technology's reported carbon emissions
BrightGene Bio-Medical Technology, headquartered in China (CN), currently does not have publicly available carbon emissions data for the most recent year. As a result, specific figures regarding their Scope 1, 2, or 3 emissions are not provided. In the absence of detailed emissions data, it is important to note that BrightGene has not outlined any specific reduction targets or commitments to climate initiatives. This lack of information suggests that the company may still be in the early stages of developing a comprehensive climate strategy or may not have publicly disclosed its commitments. As the industry increasingly prioritises sustainability and carbon neutrality, it will be essential for BrightGene to establish clear climate commitments and reduction targets to align with global efforts in combating climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
BrightGene Bio-Medical Technology is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
